BTS-GROUP
6.1.2020 15:37:14 CET | Business Wire | Press release
BTS GROUP AB (publ), a leading global strategy implementation firm, has agreed to acquire the operations and all the assets of Rapid Learning Institute LLC based in Philadelphia (USA). Through its products and solutions Rapid Learning offers a differentiated approach to leadership and sales microlearning to clients in North America.
With the acquisition of Rapid Learning, BTS will gain a library of more than 200 proprietary learning modules centered on 5- to 7-minute research-backed videos, and in addition a collection of more than 2,500 articles on leadership and sales authored by the company’s editorial team. Rapid Learning’s Micro-First method to online training gives BTS thought leadership in single-concept learning facilitated by line leaders in the flow of work. The company will also bring a set of clients who subscribe to RLI’s programs or license its content. Its inside sales expertise and customer success management experience will help BTS increase its market penetration and expand its base of recurring revenue streams.
Rapid Learning was established in Philadelphia in 2008. Since then it has developed into a respected provider of leadership and sales micro-training to hundreds of clients. Its revenues over the last twelve months are approximately 2.8 MUSD. The company has 20 employees.
The executives of Rapid Learning, Stephen J. Meyer, Rob Krekstein and Michael Boyette, have agreed to stay on with BTS to drive the organization’s continued growth. An MBA graduate of the Wharton School at the University of Pennsylvania and founder of Rapid Learning, Meyer is an accomplished journalist, editor and publisher, having contributed to Forbes and Advertising Age and headed both editorial and marketing for more than two dozen employee development publications.
“We are delighted to welcome Rapid Learning to BTS,” says Henrik Ekelund, Founder & CEO of BTS. “This team creates impressive results for their clients through a comprehensive content library combined with a proven approach to leadership and sales learning in the flow of work. Together we will become an even stronger partner in the marketplace and accelerate our growth.”
“We are truly excited to become a part of the BTS family,” says Meyer, CEO of Rapid Learning. “We share the same approaches and points of view, which will make for an excellent fit. Being part of a global firm will also be a great opportunity for our customers and colleagues."
“And we believe our digital solutions and approach are a perfect complement to BTS’ current offerings,” adds Krekstein, Vice President of Sales for Rapid Learning.
“The addition of Rapid Learning to the BTS family strengthens substantially our digital content assets and thought leadership,” says Dave Ackley, Executive Vice President and Global Head of Digital at BTS. “The team brings us scalable digital solutions our clients expect and will support our efforts to build recurring license revenue.”
The acquisition includes an initial cash consideration. An additional payment will be paid out in 2023 provided the purchased operations meet specific targets 2020-2022.
BTS' strategy for acquisitions aims to create a broader base for future organic growth while actively consolidating in a highly fragmented market. Through its acquisitions, BTS also seeks to broaden its customer base and offering by bringing in new, existing and innovative services based on state-of-the-art digital technologies.
About BTS Group AB
BTS focuses on the people side of strategy, working with leaders at all levels to help them make better decisions, convert those decisions to actions and deliver results. At our core, we believe people learn best by doing. For over 30 years, we've been designing fun, powerful experiences that have a profound and lasting impact on people and their careers. We inspire new ways of thinking, build critical capabilities and unleash business success. It’s strategy made personal.
BTS is publicly traded on the Nasdaq Stockholm exchange under the symbol BTS B.
For more information, please visit www.bts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005626/en/
Contact:
For more information, please contact: David Ackley Executive Vice President BTS Digital dave.ackley@bts.com +1.646.378.3535 Michael Wallin Head of investor relations BTS Group AB michael.wallin@bts.com +46-8-587 070 02 +46-708-78 80 19
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
